STOCKS TELEGRAPH

Author: Nicholas K

  • Profitable Stocks to Trade Today for  Exponential Gains

    Profitable Stocks to Trade Today for  Exponential Gains

    Aptinyx Inc [NASDAQ: APTX]

    Clinical-stage biopharmaceutical company Aptinyx Inc., reported today of its positive results from the second phase of its novel NVDA receptor module, NYX-783 clinical trial.

    The study involved 153 patients suffering from post-traumatic-stress disorder (PTSD). In this study, NYX-783 showed statistically and clinically significant efficacy results of this treatment. Following these results, Aptinyx expects to kick-start a serious study in 2021. PTSD is one of the most difficult psychiatric conditions to treat due to multiple debilitating symptoms.

    Murray Stein, the Vice-Chair for Clinical Research in Psychiatry at the University of California San Diego says that it is encouraging to get such positive results and considering the short duration that NYX-783 takes to cure this disorder.

    Uxin Ltd [NASDAQ: UXIN]

    Uxin Limited, an international online Chinese company dealing with used cars recently announced that it has entered into two definitive agreements with two investors that will see the company raise US$25,000,000.

    In these agreements, Uxin plans to issue an aggregate of 84,692,839 Class A ordinary shares through private placements that will occur in October 2020. Additionally, Uxin also entered into a letter agreement with affiliates of TPG, 58.com and Warburg Pincus to alter the conversion of price of the convertible notes in an aggregate total of about US$230 million.

    Based on this letter in two years after the agreement, if the Company issues or sells any equity securities less than the conversion price, the strategic investors will have a right to convert all or a part of their convertible notes at a price that is equal to New Issue Price.

    Iterum Therapeutics Plc  [NASDAQ: ITRM]

    Iterum Therapeutics plc announced today that it will present its data at the Infectious Disease Society of America IDWeek that will take place virtually as from October 21, 2020.

    The data presentations will include results for SURE-2, that will show the effects in complicated urinary tract infections (cUTI) and oral abstract presentation that are results from SURE-1 in uncomplicated urinary tract infections..

    This data shows that oral sulopenem was statistically stronger than oral ciprofloxacin to treat patients with uncomplicated urinary tract infections. Iterum Therapeutics is a clinical-stage pharmaceutical institution that is focussed on developing oral and IV antibiotics for the treatment and management of infections caused by drug resistant pathogens in both hospital and home settings.

  • BOQI International Medical Inc [BIMI] Rallies After 1026% Revenue Growth

    BOQI International Medical Inc [BIMI] Rallies After 1026% Revenue Growth

    BOQI International Medical Inc [NASDAQ:BIMI] is one of the top performers this afternoon, at a time when key indices have turned negative. The stock is currently up by over 50% and gaining. It’s upside momentum follows the release of stronger than expected Q2 results, including a huge increase in revenues compared to a similar period last year.

    Breaking down the results, the company announced that total revenues rose by over 1026% compared to Q2 of 2019. The company also announced that its gross profit margins rose by 22.77% a significant increase when compared to Q2 of 2019 when it recorded a gross profit margin of 4.35%. The company also reported that its net income in Q2 of 2020 rose by 629% when compared to Q2 of 2019.

    The company attributed its strong revenues growth to Guanzan Group’s sales of generic medications and medical devices. Guanzan Group is the latest asset purchase by BOQI International and one that has proven to be pivotal to the company’s revenue growth in Q2.

    The revenue growth was also attributed to the sale of products made by t NF Group. It also attributed its revenue growth to the provision of technical services and partnerships in product processing services. The company’s gross profit margins for the quarter wholesale business mainly in the wholesale medical devices and wholesale medical segments which both grew by over 20% in the quarter.

    The company’s net profits also recorded massive growth compared to a similar quarter in 2019. In specifics, the company reported a net profit of $4,673,854 when compared to a net loss of $883,245 in a similar period in 2019.

    The company attributed the increase in net profits to money made from the sale of the NF Group. The company’s liquidity position also improved from $36,674 to $109,402.

    Commenting on the results, CEO Tiewei Song said that they were happy with the Q2 results. He added that they had bought Guanzan Group allowing them to better align with the present business environment and long term growth.  He added that with more healthcare facilities opening up, the company expected demand for its products to rise, thereby adding value to the company’s shareholders.

    About BOQI International Medical Inc

    BOQI International Medical Inc is a distributor of pharmaceuticals and other healthcare products. The company runs through a network of 16 stores and mainly distributes its products in China. It is headquartered in Dalian, China.

  • Stocks to Watch as Stimulus Hopes Uplift Markets

    Stocks to Watch as Stimulus Hopes Uplift Markets

    The key indices are all up this morning with the Dow, the NASDAQ, and the S&P 500 all in positive territory. This follows news that there could be a stimulus package before the elections.  Comments by lawmakers over the weekend indicated that a COVID-19 relief could come before November 3rd.

    Elsewhere, President Trump stated that he was aiming for a higher number than what House Speaker Nancy Pelosi had requested, following a move by house democrats to put forth a $2.2 trillion package. Essentially this means that the President was willing to go with a number that is higher than the $1.8 trillion that he had proposed earlier.  This is a positive development for an economy that has been badly by the COVID-19 pandemic.

    As of Saturday, the number of COVID-19 cases had risen to more than 57k. While it was an improvement from earlier figures, it still shows that the virus was still a major burden to the U.S economy. The positive start to the week is also an indicator of optimism in the global economy, following data from China showing that the economy grew by 4.9% in Q4. Riding on this improved sentiment, there are several stocks that are poised to do pretty well in the day. Some pre-market gainers that are headed for a strong day are as below:

    Code Chain New Continent Limited [NASDAQ: CCNC]

    Code Chain New Continent Limited is a top performer pre-market and is up by over 160%. While there are no current news driving stock, a week ago, it emerged that insiders have been loading up on the stock. Over the last 12 months, the company’s Co-Chairman of the Board bought the stock and his single largest purchase was worth $955,000. Normally, insider buying usually points to confidence in a company’s fundamentals. This is driving this stock’s momentum and could be instrumental in its long term value play.

    CHF Solutions Inc [NASDAQ: CHFS]

    CHF Solutions Inc is one of the best performers pre-market and is up by over 2000%. This follows news that data showed that Aquadex Therapy was beneficial in treating heart failure and COVID-19.  This has excited the markets leading to the massive run-up in price.

    Kaixin Auto Holdings [NASDAQ: KXIN]

    Kaixin Auto is a top performer pre-market and is up by over 50%. This stock has no news at the moment. This means it is riding the positive sentiment that has gripped the entire market. It will be an interesting stock to watch in the day.

     

  • Hot Stocks to Watch Today for Massive End Week Gains

    Hot Stocks to Watch Today for Massive End Week Gains

    The stocks are up after several days of losses and there are stocks that are already outperforming the market in early morning trading. Some of the stocks leading the day’s upside momentum are as below:

    Flexible Solutions International, Inc [NYSE: FSI]

    Flexible Solutions International, Inc today announced year over year increase in revenue for the third quarter of the fiscal year 2020. The company is a leading manufacturer of detergent ingredients, polymers for oil extraction, and water treatment solutions. It also manufactures environmentally safe and biodegradable energy and water conservation technologies.

    In over just one year, sales revenue increased by 10%, from $7.4 million in Q3, 2019, to $8.11 million in Q3, 2020. Dan O’Brien, the Chief Executive Officer welcomed this growth saying that the company is pleased and is gearing to keep that momentum throughout the rest of the year.

    FSI will present its year-end financial results on November 13, 2020, after the market close. It will have a conference call on November 16, 2020, for this purpose.

    MMTEC Inc [NASDAQ: MTC]

    MMTEC, a Chinese technology company that gives access to the U.S. financial markets announced today its financial results for the six months ending June 30, 2020. The company has seen tremendous growth in the six months following the merging of MMBD Trading Limited, and MM Global Securities, Inc., as part of the company. Revenues grew from $177,543 to $329,070, an 85.35%. The revenue has largely been due to commission fees accrued brokerage services. The company’s gross profit saw a significant increase of 189.27% to about $322,044 from $111,328 in 2019 for the same period. Operational loss reduced from $1,308,583 to $1,041,361 in the six months as a result of an increase in revenue, and a subsequent decrease in administration, payroll, and marketing costs.

    ASLAN Pharmaceuticals Ltd [NASDAQ: ASLN]

    Clinical-stage and biopharmaceuticals company ASLAN Pharmaceuticals, announced today its plans to develop ASLAN003 as its next-generation oral inhibitor of DHODH (dihydroorotate dehydrogenase) for autoimmune diseases like multiple sclerosis.The company says that the medication will have 30 times more potency as compared to teriflunomide. The medication is highly selective and a strong inhibitor of the DHODH enzyme in both cell-based and cell-free assays. It is highly effective in pre-clinical studies done on animal models as well as showing promise in terms of safety and efficacy. The company considers it the most viable candidate for the next clinical-trials in the treatment of the mentioned condition.

  • Pelaton Interactive Inc [NASDAQ: PTON] – Why Its Projected to Test $140 Soon

    Pelaton Interactive Inc [NASDAQ: PTON] – Why Its Projected to Test $140 Soon

    Peloton Interactive Inc [NASDAQ: PTON], a fitness and exercise equipment company had its shares rise after a bullish analyst increased his price. Peloton has seen its share price rise by 470% in the last year, raising the value of the company to $37.9 billion. COVID-19 pandemic played a significant role in its growth as gyms closed down forcing most people to workout at home. The bullish analysts are expecting this trend to continue even after the gyms reopen.

    According to FactSet, the mean price current target is about $116.33 even though the stock is mostly bought from Wall Street analysts.  A few bullish analysts have set their targets lower than the current level, but might be forced to evaluate their models to catch up or bring down their ratings.

    Some analysts that have raised their targets to include;

    Jonathan Komp, a Baird analyst that has raised his from $120 to $140. He expects Peloton momentum to continue.

    Truist analyst Youssef Squali on Wednesday raised his projection from $115 to $140 following a survey that interviewed about 1,500 consumers checking on their exercise habits. The survey painted a good picture of the future of the exercise equipment market.

    Out of 1,169 respondents that exercised at home, at least 54% bought a piece of equipment to work out at home. 40% of those who made such purchases said that they had no plans to buy the exercise equipment before the pandemic, while 23% of those planning to buy some sort of equipment is projecting to spend more than$1000. 19% of those planning to make such purchases named Peloton as their brand of choice. It was the highest-ranked. Out of those who name Peloton, 44% are from households making less than $75,000, discrediting the notion that Peloton is a brand for only a specific niche of affluent clientele. 32% of them were between 18 to 34 years. This data shows that the brand is not only for less affluent individuals but also is a choice for most young people.

    Following these developments, Peloton share price rose by 0.4% to a closed on a new high of $131.4 on Wednesday, while the S&P index went down by about 0.7%. The current excitement of the company’s stock and its run on Wall Street is pushing the bar high for the company’s earnings reports to come next month. It is currently trading at 9.61 times that the estimated price for the next 12 months. It must maintain its bullish run to cushion it on Wall Street

  • Stocks to Watch as Unemployment Numbers Tank Markets

    Stocks to Watch as Unemployment Numbers Tank Markets

    SPI Energy Co., Ltd. [NASDAQ: SPI]

    SPI Energy Co., Ltd., a world renewable energy company, and a manufacturer of electric vehicles and photovoltaic solutions for residential, business, logistics, government and utility clients announced today that its fully owned subsidiary, EdisonFuture will be signing a strategic cooperation framework agreement with China’s leading manufacturer of all-electric motor vehicles Tongjia. According to the agreement terms and conditions, the two signatories will work together to design, develop, produce and sell a new generation of smart electric logistics vehicles and electric trucks. Tongjia will be supplying parts to the EdisonFuture assembly plant in California where the vehicles will be assembled. The assembly will also include the installation of software.

    Organogenesis Holdings Inc [NASDAQ: ORGO]

    Organogenesis Holdings Inc., a medical company whose focus is on the development, manufacture, and sale of advanced wound care as well as surgical and sports medicine products released today a preliminary report of their financial results for the three months ending September 30, 2020. According to the report, the company has recorded an increase in net revenue from $64.3 million to $99 million. Sale of Advanced Wound Care products, Surgical & Sports Medicine, and Puraply have recorded an increase in sales contributing to the net sales. In the coming financial year, the company expects a rise in revenue by about 19% to 20%, which will be about $311 and $314 million. Following these projections, the company expects to report an increase in GAAP net income as well as a positive EBITDA for the three months ending December 31, 2020.

    PREIT [NYSE: PEI]

    PREIT an international operator of retail and experiential destinations announced yesterday that it has sign agreements with more than 80% of its bank lenders in a move that will see the company secure $150 million to revamp its business and prolong its debt maturity schedule. This loan will go into expanding the company’s operations and executing planned strategic activities.  The company’s Chief Executive Officer Joseph Coradino said that they have been repositioning their business to strengthen their capital base by actively selling some of their assets and diversifying their tenant base in a bid to get more capital. They have now managed to secure the $150 million that will see them revamp their business and have financial flexibility.

  • Interpace Biosciences [IDXG] Rockets after Beating Complaint

    Interpace Biosciences [IDXG] Rockets after Beating Complaint

    Interpace Biosciences, Inc [NASDAQ: IDXG] announced today that the Board of Directors Audit Committee found the complaints regarding some billing and employment issues that have been raised to be invalid. After a thorough independent investigation, the committee said that the allegations raised were unsubstantiated since there was no evidence of any illegal activities.

    Company employees, including one that has since terminated their contract, sent letters to the company raising the employment and billing compliance issues. These issues arose from the company’s requirements as in its Notification of Late Filing on Form 12b-25 filing that showed the firm’s inability to meet the deadlines to file Form 10-Q for that quarter ended June 30, 2020. Interpace responded by forming an Audit Committee, an independent registered public accounting firm, and a Regulatory Compliance Committee to investigate the issues those employees had brought forth.

    The committees commenced with the investigations and carefully looked into every issue raised. They received assistance from an independent counsel and advisors to avoid any overlapping issues. After the completion of the investigation, the investigating team concluded that the claims were not substantiated and that there were no claims or evidence of illegal acts.

    Who is Interpace Biosciences?

    Interpace Biosciences is one of the emerging medical sciences firms that focus on personalized medicine. Among the services, the company offers to include specialized therapeutic services, early diagnosis, and therapeutic applications through a value chain that sees patients get special care. Further, the company uses the latest technology in the area of personalized medicine for patient diagnosis and management. They use diagnostic tests, pathology services, and bioinformatics to evaluate the risk of cancer.

    As of the moment, Interpace has four molecular tests that have already been commercialized, and another that is currently at its clinical evaluation stage (CEP). The four molecular tests are

    • PancraGEN: Diagnosis and prognosis of cancer of the pancreas emerging from pancreatic cysts.
    • ThyGeNEXT: Diagnosis of thyroid cancer emerging from thyroid nodules. It uses next-generation sequencing assay
    • ThyraMIR: Diagnosis of thyroid cancer also from thyroid nodules. This one uses proprietary gene expression assay
    • RespriDX: Helps differentiate primary versus metastatic origin lung cancer.

    The test that is at the CEP stage is a molecular-based assay, BarrenGEN that will help stop the progression of Esophagus Barrent into fully blown esophageal cancer.

    Interpace also works with Pharma services to provide other solutions that include genotyping, testing, biorepository, and other important services in this industry.

     

     

     

     

  • Why Naked Brand Group Limited [NAKD] could retest its Mid-year Highs

    Why Naked Brand Group Limited [NAKD] could retest its Mid-year Highs

    Naked Group Limited [NASDAQ: NAKD] is trading at a key support level and has the potential to test new highs short-term. This follows a recent announcement that the company had regained its listing in the NASDAQ. The Listing Qualification Department of the NASDAQ market has sent a letter to the Naked Brand group notifying them that they have regained compliance with the requirements limits of the market to continue listing on that market. Naked Brand, according to Nasdaq, now complies with Listing Rule 5550 (b). The rule requires that a company like Naked have $2.5 million as its minimum stockholder’s equity. This requirement is for companies that depend on equity standards to continue being listed. Naked complied with the Capital market listing requirements after completing transactions as prescribed on Form 6-K that it filed today with the SEC.

    Anna Johnson, Naked’s Chief Executive Officer thanked the company’s investors for patiently waiting, as the company’s management team in collaboration with the board of directors worked tirelessly to ensure that Naked got back its compliance. She further reiterated that, with the matter of compliance now under the carpet, and having gotten back the listing, Naked will now direct its efforts towards growing the company and ensuring that the shareholders and investors get value for their investments.

    The listing promises good returns for investors as Naked products will soon regain consumers’ confidence that it had lost a great deal. This listing also comes as an attraction to more investors whose investments will boost the growth of the company and help grow its brand. The extra investment will go a long way into revamping the company, acquiring new assets, and increasing production and as a result distribution. They are also set to significantly increase sales in the coming financial year and further strengthen their stock. There can only be good tidings going forward and increased returns, thus a good time for investors.

    Who is Naked Brand Group Limited?

    Naked Brand Group is a multinational company that deals with intimate clothing and swimming apparel with a range of portfolios. The company has a range of brands ran by smaller establishments with Naked being the mother company. As of the moment, the company has eight licensed brands that serve a wide range of markets and consumers. Naked controls and manages the entire process of designing, manufacturing, and distributing their apparel to their respective markets and consumers. Brands under this multinational include Bendon Man, Bendon, Fayreform, Hickory, Davenport, Lovable, Fredericks of Hollywood, and Pleasure State. These brands serve all genders across the world.

  • High Potential Stocks on a Mixed Day in the Markets

    High Potential Stocks on a Mixed Day in the Markets

    It’s a mixed day in the equity markets with the S&P index sinking in the red in pre-market trading.  The NASDAQ and the Dow are also oscillating between positive and negative territory too, an indicator of market indirection. This comes amidst falling bank profits due to the COVID-19 pandemic. One bank that has released weak quarterly results is Bank of America. The bank’s Q3 net income to 0.51 cents per share, from profits of $0.56 in a similar quarter in 2019. Total revenues also dropped by 10.8% to stand at $20.34 billion. The bank’s net interest income also fell by 16.9% and missed consensus estimates of $10.24 billion. The company has attributed this to the pandemic and has created jitters in the market on the massive impact of COVID-19 on the economy. On top of that, hopes of a vaccine have been dashed after Johnson & Johnson stopped its vaccine trials after one person developed an unexplained illness. While this is likely to affect the market negatively, the markets are likely to show some strength due to the hopes of a stimulus package, hence the mixed scenario. Despite the mixed market sentiment, there are stocks that stand to perform quite well in the day. Some of the high potential stocks to watch today are as below:

    Medalist Diversified REIT Inc [NASDAQ: MDRR]

    Medalist Diversified REIT Inc is a top performer pre-market and is up by over 100%. This follows the company’s announcement that it was giving a cash dividend for its series A preferred stock.  The dividend will be paid on the 26th of October 2020 to all series A stock held by the 23rd of October. This has created buying pressure in this stock as investors move to buy the stock ahead of the upcoming dividend.

    Xcel Brands Inc [NASDAQ: XELB]

    Xcel Brands Inc is a top performer this morning and is up by over 30%. This momentum is largely driven by insider buying that happened on 8th, October 2020.  On that date, the CEO purchase 4k shares at $0.75. Weeks earlier, one of the company’s directors had purchased 10k share at $0.72. This means insiders are confident in the company’s fundamentals.

    Allscripts Healthcare Solutions Inc [NASDAQ: MDRX]

    Allscripts Healthcare Solutions Inc is in the green pre-market and is up by over 30%. This follows the company’s announcement that it planned to sell Careport Health. The company has announced that it would be selling CarePort business for $1.3 billion.

  • Medley Capital Corporation [MCC] Could Test $25 After Deal with Golub Capital LLC

    Medley Capital Corporation [MCC] Could Test $25 After Deal with Golub Capital LLC

    Medley Capital Corporation [NYSE: MCC] has sustained gains since last week.  This follows last week’s announcement that it has entered into a Membership Interest Purchase Agreement together with MCC Senior Loan Strategy JV LLC, the other partner with interests in MCC JV and a member of Golub Capital LLC with Golub LLC, in which Golub LLC purchased both MCC and MCC JV Interests for a total of $156.4 million. The purchase is subject to various adjustments, following the terms and conditions set in the purchase agreement.

    Following this transaction, MCC JV has managed to pay in full all of its outstanding borrowings and ended its senior secured revolving credit facility. This facility was dated August 4, 2015, after Deutsche Bank AG, the New York Branch amended it. These repayments and adjustments have had a significant positive impact on the two establishments. In addition to debt repayment, the two establishments, MCC and MCC JV received some proceeds. They received $41.0 million and $6.6 million.

    The Chair of the MCC special Committee, David Lorber said that they believe that the transaction is significant for MCC, as it is set to improve the firm’s liquidity and strengthen its balance sheet giving it a positive edge. Both companies are now out of debt and on their way to making massive profits. The special committee that saw the success of this transaction received advice from Houlihan Lokey.

    About Medley Capital Corporation

    A closed-end business establishment Medley Capital Corporation is externally managed and has common stocks and outstanding bonds both of which are traded on the New York Stock Exchange. The stock trades under the symbol (NYSE: MCV), and the bonds under the symbol (NYSE: MCX). The company aims to generate current income and capital appreciation. The company lends to private firms in the middle market through direct originated agreements, to help the firms grow their business and acquire new assets. MCC is externally advised and is registered under the Investment Advisers Act of 1940.

    About MCC Advisors LLC

    Medley Advisors LLC are the primary advisors of Medley Capital Corporation. The advisors are under Medley Management, an asset management company that controls about $3.6 billion worth of assets. It manages these assets under two companies, Sierra Income Corporation and Medley Capital Corporation. The firm has financed over 400 companies across 35 industries in the United States and North America for over 18 years. Medley LLC has bonds trading in the New York Stock Exchange (NYSE: MDLX) and (NYSE: MDLQ).